HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have entered into a clinical trial collaboration to evaluate a new combination therapy for the treatment of clear cell renal cell carcinoma (ccRCC), a common form of kidney cancer. The partnership will explore the potential of casdatifan, Arcus's investigational HIF-2a inhibitor, in conjunction with AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, volrustomig.
The collaboration aims to establish a potential first- and best-in-class treatment by leveraging the unique mechanisms of both drugs. Casdatifan is currently being assessed in a Phase 1/1b study for its efficacy in cancer patients, while volrustomig has shown encouraging efficacy as monotherapy in a first-in-human study for advanced ccRCC.
AstraZeneca will sponsor and conduct a study to evaluate the safety and early efficacy of the combination therapy in patients with advanced ccRCC. This marks the second clinical collaboration between the two companies, following a 2020 agreement to study a combination therapy for non-small cell lung cancer.
Kidney cancer ranks among the top 10 most commonly diagnosed cancers in the U.S., with an estimated 81,600 Americans expected to be diagnosed in 2024. The five-year survival rate for advanced or metastatic ccRCC is notably low at 15%, highlighting the need for new treatment options.
Both casdatifan and domvanalimab, another molecule developed by Arcus, are investigational and have not yet received approval from any regulatory authority. Their safety and efficacy remain to be established.
The collaboration between Arcus and AstraZeneca, as well as the potential involvement of Gilead Sciences (NASDAQ:GILD), which has an opt-in right for casdatifan's development and commercialization, represents a concerted effort to improve outcomes for patients with ccRCC. This article is based on a press release statement from Arcus Biosciences.
In other recent news, AstraZeneca reported stable voting rights and share capital, with its issued share capital consisting of 1,550,294,658 ordinary shares, each with a nominal value of US$0.25. The company's ENHERTU, developed with Daiichi Sankyo, received FDA Priority Review based on results from the DESTINY-Breast06 Phase III trial. However, the TROPION-Breast01 Phase III trial reported mixed results. Erste Group revised its rating for AstraZeneca from Buy to Hold, while Deutsche Bank (ETR:DBKGn), BMO Capital, TD Cowen, and BofA Securities maintained positive outlooks.
AstraZeneca's TAGRISSO gained FDA approval for the treatment of Stage III epidermal growth factor receptor-mutated non-small cell lung cancer, based on the LAURA Phase III trial. This approval marks a significant advancement for patients with this specific type of lung cancer. The FDA also approved AstraZeneca's FluMist influenza vaccine for self-administration at home and Fasenra for the treatment of adult patients with a rare immune-mediated vasculitis. These are among the recent developments in the ongoing advancements of AstraZeneca.
InvestingPro Insights
AstraZeneca's collaboration with Arcus Biosciences to develop a new combination therapy for kidney cancer aligns with the company's strong position in the pharmaceutical industry. According to InvestingPro data, AstraZeneca boasts a substantial market capitalization of $245.99 billion, underlining its significant presence in the sector.
The company's focus on innovative treatments is reflected in its robust financial performance. AstraZeneca's revenue growth of 10.45% over the last twelve months and a quarterly revenue growth of 13.33% in Q2 2024 demonstrate its ability to expand its market share and potentially capitalize on new therapeutic opportunities like the ccRCC treatment.
InvestingPro Tips highlight AstraZeneca's financial stability and growth potential. The company is expected to see net income growth this year, and analysts predict it will remain profitable. This financial strength provides a solid foundation for investing in research and development, crucial for partnerships like the one with Arcus Biosciences.
Moreover, AstraZeneca's commitment to shareholder value is evident in its 32-year streak of maintaining dividend payments. This consistency, coupled with the company's moderate debt levels and ability to cover interest payments with cash flows, suggests a balanced approach to financial management and investment in future growth opportunities.
For investors interested in a deeper analysis, InvestingPro offers 13 additional tips for AstraZeneca, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.